Tixupharma
Repair Acute and Chronic Joint Diseases
Epitros therapy in Arthropathy
Ubigenine-plus is an emerging candidate disease-modifying, while first-in-class candidate therapeutic for underserved arthropathies.
The clinical efficacy is sustained by preclinical models and preliminary case series in joint diseases - where just symptomatic medications are available - upon limited non-cumulative doses.
Osteoarthritis (OA)
Chronic disorder involving movable joints characterized by cell stress and extracellular matrix degradation initiated by micro- and macro-injury that activates maladaptive repair responses including pro-inflammatory pathways of innate immunity. An initial molecular derangement (abnormal joint tissue metabolism) is followed by anatomic/physiologic disarrays characterized by cartilage degradation, bone remodeling, osteophyte formation, joint inflammation and loss of joint function. OA affects hands, knees, hips and spine of millions of people worldwide, prevalence rumps up after the 50th year of age. It is managed by NSAIDS and steroids without reversing the joints damage, while preventive measures may slow down disease progression.
Tendinopathy
This painful conditions occurs in and around tendons in response to overuse as multifaceted disease marked by decline in tendon function and reduced exercise tolerances, Tendinitis appears earlier in life due to overuse, typically of rotator cuff tendon, epicondyles, patellar tendon, gluteal tendons, Achilles tendon. Chronic tendinosis shows up on aging manifested as increased collagen disarray, microvasculature&sensory nerve innervation, surge of inflammatory mediators, enhanced cell apoptosis, and fat infiltration. Little or no COX-related inflammation is present in the conditions. Thus, traditional treatment modalities aimed at controlling inflammation such as corticosteroid injections and NSAIDS may not be the most effective options.